Skip to Main Content Go to Sitemap
SickKids

Petros Pechlivanoglou

Title: Senior Scientist, Child Health Evaluative Sciences
Designations: PhD, M.Sc.
Phone: 416-813-7654 ext. 309484
Email: petros.pechlivanoglou@sickkids.ca
Alternate Contact Name: Yanara Marks
Alternate Phone: 416-813-7654 ext. 309975
Alternate Email: yanara.marks@sickkids.ca
U of T Positions: Associate Professor, Institute of Health, Policy Management and Evaluation, Dalla Lana School of Public Health
Other Positions: Adjunct Scientist, Cancer Research Program, Institute for Clinical Evaluative Sciences

Biography

Petros Pechlivanoglou, PhD, is a Senior Scientist at The Hospital for Sick Children (SickKids) Research Institute and an Associate Professor at the University of Toronto, Institute of Health Policy Management and Evaluation. He studied economics in his native country, Greece, econometrics at the University of Groningen, the Netherlands, and obtained a PhD in health econometrics from the same university.

He completed a post-doctoral fellowship at the University of Toronto, within the Toronto Health Economics and Technology Assessment (THETA) Collaborative where he focused on methodological aspects around the application of decision analysis in health-care policy.

Research

Dr. Pechlivanoglou’s research interests focus on methods and applications of decision analysis in health economics, bridging evidence synthesis, administrative data and decision analysis, and the application and extension of predictive models in health economics.

He has received funding from the Canadian Institute for Health Research, the Canadian Respiratory Research Network, and more recently, the Ontario Early Researcher Award to work on projects around the economics of pre-term birth prevention, the economic evaluation of oncology interventions in children and adolescents, the use of decision analysis in paediatric clinical trial design, and the economic impact of COPD in adults.

Education

  • 2013–2015: Postdoctoral Fellow, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada  
  • 2007–2012: PhD, in Pharmacoeconomics, Unit of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Pharmacy, University of Groningen, The Netherlands 
  • 2005–2007: M.Sc., in Econometrics, Faculty of Economics, University of Groningen, Groningen, The Netherlands
  • 2001–2005: B.Sc., in Economics, Faculty of Economic Sciences, University of Macedonia, Thessaloniki, Greece

Experience

  • 2022–Present: Senior Scientist. The Hospital for Sick Children, Toronto, ON
  • 2022–Present: Associate Professor. Institute of Health, Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON
  • 2020–Present: ICES Adjunct Scientist. Cancer Research Program, ICES, University of Toronto, Toronto, ON 
  • 2016–2022: Assistant Professor. Institute of Health, Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON 
  • 2015–2022: Scientist. The Hospital for Sick Children, Toronto, ON 
  • 2013–2015: Health Economist. Toronto Health Economics and Technology Assessment (THETA) Collaborative Toronto, ON 
  • 2010–2012: Assistant in Training (AIO). Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands 
  • 2007–2010: Research Associate. Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands 

Achievements

  • 2019: The Nancy E.T. Fahrner Award – $3,000 (CAD) The Hospital for Sick Children, University of Toronto
  • 2019: Member of Health Economics Advisory Council, Canadian Agency for Drugs and Technologies in Health
  • 2019: Editorial board: Medical Decision Making Journal
  • 2019–2024: Ontario Early Researcher Award – $150,000 (CAD) – Government of Ontario
  • 20172018: Greek Diaspora Fellowship – 8,000 (Euros) –The Stavros Niarchos Foundation, Greece
  • 20072010: Dutch Bursary Ph.D. Scholarship – 51,000 (Euros) – Groningen University, The Netherlands

Publications

  1. Furzer J, Gupta S, Nathan PC, Schlechter T, Pole JD, Krueger J, Pechlivanoglou P. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. JAMA Oncology. 2020 Jan. [Epub ahead of print]. 
  2. Tessier L, Furzer J, Hodgson D, Cotton C, Nathan PC, Gupta S, Pechlivanoglou P. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin’s Lymphoma. Journal of the National Cancer Institute. 2020 Jan 1; 112(1):63-70.
  3. Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MGM, Pechlivanoglou P. (2018). Microsimulation modeling for health decision sciences using R: A tutorial. Medical Decision Making. Apr 2018; 38(3):400-422.
  4. Pechlivanoglou P, Abrahamyan L, MacKeigan L, Consiglio GP, Dolovich L, Li P, Cadarette SM, Rac VE, Shin J, Krahn M. Factors affecting the delivery of community pharmacist-led medication reviews: Evidence from the MedsCheck Annual service in Ontario. BMC Health Serv Res. Nov 2016; 16(1):666.
  5. Pechlivanoglou P, Wieringa JE, de Jager T, Postma MJ. (2015). The effect of financial and educational incentives on rational prescribing. A state-space approach. Health Econ. Apr 2015; 24(4):439-53.

  • 2019–2021: Co-Applicant. Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells. OICR-CCO Health Services Research Total Funding - $297,217Principal Investigator: Kelvin Chan 
  • 2019–2024: Principal Investigator. Ontario Early Researcher Award: Developing the Pediatric Oncology Simulation Model. Ministry of Research and Innovation, Government of OntarioTotal Funding - $100,000 (Host Institution matched $50,000 for a total of $150,000) 
  • 2019–2022: Co-Applicant. Economic impact of falls prevention interventions: We know the “value”, but what about the “value for money”? Canadian Institutes of Health Research (CIHR), Project Grant. Total Funding - $306,000Principal Investigator(s): Wanrudee Isaranuwatchai; Andrea Catherine Tricco. 
  • 2018–2021: Co-Applicant. Optimizing Resource Allocation in the NICU to Improve Outcomes of Very Preterm Infants. Canadian Institutes of Health Research (CIHR), Early Career Investigator Grants in Maternal, Reproductive, Child & Youth Health. Total Funding - $105,000 (Host Institution matched funds 1:1 for a total of $210,000)Principal Applicant: Marc Beltempo. 
  • 2018–2021: Principal Investigator. Rationalizing Genetic Referral Practices in Pediatric Oncology: An eHealth Decision-Support Tool for Identifying Cancer Predisposition Syndromes. Canadian Institutes of Health Research (CIHR) Project GrantTotal Funding - $325,124Principal Investigator: Catherine Goudie. 
  • 2018–2020: Co-Applicant. Performance and cost-effectiveness of a prediction tool to identify cancer predisposition syndromes in children with cancer. Cancer Research SocietyTotal Funding - $120,000Principal Investigator: Paul Nathan. 
  • 2018–2026: Co-Applicant. Optimizing outcomes in survivors of childhood, adolescent and young adult cancer. Canadian Institutes of Health Research (CIHR)Total Funding - $2,729,448Principal Investigator: Paul Nathan. 
  • 2017–2019: Co-Applicant. Healthcare utilization and costs associated with current and future treatment strategies for childhood acute lymphoblastic leukemia: Building a policy model for clinicians and funders. Children's Cancer and Blood Disorders C17 Research Network Grant Competition Total Funding - $120,000Principal Applicant: Sumit Gupta. 
  • 2017–2019: Co-Applicant. Developing a framework for the incorporation of real world evidence into cancer drug funding decisions in Canada. Canadian Institutes of Health Research (CIHR) Operating Grant: Partnerships for Health System Improvement for Cancer ControlTotal Funding - $970,638Principal Applicant: Kelvin Chan. 
  • 2017–2018: Co-Applicant. A Multi-Province Approach to Real World Evidence Development for Cancer Drugs: A Case Study of Melanoma. Canadian Institutes of Health Research (CIHR), Catalyst Grant: Health Services and Economics Research in Cancer ControlTotal Funding - $98,925Principal Investigator(s): Kelvin Chan, Wanrudee Isaranuwatchai, Stuart James Peacock, Michael David Sherar. 
  • 2017–2018: Principal Investigator. Estimating the cost-effectiveness threshold for cancer care in Alberta. Catalyst Grant: Health Services and Economics Research in Cancer Control. Canadian Institutes of Health Research (CIHR) Institute of Cancer Research (ICR) Catalyst Grant. Total Funding - $98,000Nominated Principal Applicant: Eldon SpackmanCo-Applicants: Mike Paulden; Christopher McCabe. 
  • 2017–2020: Principal Investigator. Innovation in Pediatric Clinical Trials (IPCT). Canadian Institutes of Health Research (CIHR). SPOR Innovative Clinical TrialsTotal Funding - $2,437,499Nominated Principal Applicant: Terry Paul Klassen. 
  • 2017–2019: Principal Investigator. Creating a platform for prediction of real-world health and cost consequences of COPD. Canadian Respiratory Research Network Project GrantTotal Funding - $134,600Co-Applicants: Mohsen Sadastafavi; Murray Krahn; Teresa To; Nicholas MitsakakisLusine Abrahamyan. 
  • 2016–2021: Principal Investigator. Improving Outcomes for Preterm Infants and their Families: A Canadian Collaborative Network. Canadian Institutes of Health Research (CIHR)Total Funding - $4,500,000Nominated Principal Applicant: Prakeshkumar Shah. 
  • 2016–2017: Principal Investigator. Economic evaluation of chimeric antigen receptor T-cells (CART) therapy for high-risk relapsed acute lymphoblastic leukemia in children. POGO Seed Funding GrantTotal Funding - $14,984Co-Applicants: Jason Pole, Sumit Gupta, Paul Nathan, Tal Schechter-Finkelstein, Wendy Ungar. 
  • 2016–2019: Collaborator. Clinical development and translation of genomics-driven paediatric cancer diagnostics using NanoString Technology. Genomic Applications Partnership ProgramTotal Funding - $1,900,000Principal Applicant: Cynthia Hawkins; John Racher. 
  • 2016–2019: Co-Applicant. Understanding the treatment benefits of novel antiviral agents for hepatitis C: Quality of life, health utility, cost, and return to work. Canadian Institutes of Health Research (CIHR) Project SchemeTotal Funding - $615,000Principal Applicant: William Wei Wong. 
  • 2015–2016: Co-Applicant. Evaluating the cost-effectiveness of corneal cross-linking in the treatment of keratoconus in Ontario. University of TorontoTotal Funding - $10,000Principal Investigator: Wendy HatchCo-Applicant: Murray Krahn. 
  • 2014–2015: Co-Applicant. Cross sectional and longitudinal measures of quality of life and utility among patients with chronic hepatitis C virus infection. Canadian Institutes of Health Research (CIHR). Total Funding - $100,000Principal Investigator: William Wong; Murray Krahn. 
  • 2014–2017: Co-Applicant. Evaluation of Value Demonstrating Initiative on COPD. Ministry of Health and Long-Term Care, Ontario, Rx&D and the Ontario Lung Association (OLA)Total Funding - $397,675Principal Investigator: Murray KrahnCo-Investigators: Valerie RacLusine Abrahamyan; Nicholas Mitsakakis. 
  • 2014–2015: Co-Applicant. Toronto Health Economics and Technology Assessment Collaborative (THETA). Health Quality OntarioTotal Funding - $1,600,000Principal Investigator: Murray Krahn. 
  • 2013–2015: Co-Applicant. Clinical and cost-effectiveness of MedsCheck in Ontario seniors: A mixed methods study. The Blueprint for Pharmacy c/o The Canadian Pharmacists AssociationTotal Funding - $236,626Principal-Investigator: Murray Krahn. 
  • 2012: Co-Applicant. Economic evaluation of a network of new antithrombotic drugs. Health Council of the NetherlandsTotal Funding - €20,000 (Euros)Principal Investigator: Maarten Postma. 
  • 2011–2012: Co-Applicant. Economic evaluation of a network of alternative prophylaxis strategies in high-risk neutropenic patients in the Netherlands. Merck, Sharp and Dohme UKTotal Funding - $60,000Principal Investigator: Maarten Postma. 
Back to Top